Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
about
Aclidinium bromide for the treatment of chronic obstructive pulmonary diseaseAclidinium bromide for stable chronic obstructive pulmonary diseaseLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseAclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary diseasePotential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.An update on the efficacy and safety of aclidinium bromide in patients with COPD.Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).The Genuair® inhaler: a novel, multidose dry powder inhaler.The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study.
P2860
Q22306019-86366023-519A-4B4D-93E3-2C6D942BFC73Q24193506-01940BCC-3430-4058-9C39-AB7B8730190CQ27022636-2DCFB672-00AA-438D-BDD1-D2C2F9A044E2Q27023223-2AEB345D-00DA-4061-A1B1-B61AE696103EQ34336907-2CFDD48E-BB8F-4AA1-9A3A-B9B7886D6A47Q35268320-88DFA4F3-9C9B-400F-9575-438CA1A6456BQ37667100-6DB3C73D-EAC4-48F9-9E2F-816B2A339CD7Q37795391-9B34DF7F-72C8-4EEE-B7F1-0CAD82944253Q37894102-C48CA752-B10E-4E62-ACE2-07F64063AECEQ37984784-5426F8A8-65A3-4B87-BA60-943E1EEB9C96Q38052955-E8AC7052-A3B6-4ABE-BEC6-399205DD98F6Q38112092-F5A02FC3-7DD3-4F53-B3F8-1BB792CAB76DQ38287153-66B33199-0184-4139-881B-41799810CE5AQ38592062-41438A7E-8514-4152-B24B-C876371D6FA0Q43695468-B3B269C0-F6DC-4679-A336-76161D2C25AFQ43997723-8E4E95BD-BE19-43C5-A4BB-BD4C4F58A240Q45116924-61BC9C96-E7F3-4149-B847-029D4655ED5EQ47946666-92227D9F-D1F4-43F6-8B80-D1AF5ABF0CC0Q48485039-0664F34F-3BCD-4048-8D08-95A000EB50F4Q51595221-7D921FEE-EF76-4462-8D61-F9A78986819DQ52852839-F201A017-165C-4BA9-9A2D-9E7F57E41D43
P2860
Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and pharmacokinetics of ...... ease, in healthy participants.
@en
Safety and pharmacokinetics of ...... ease, in healthy participants.
@nl
type
label
Safety and pharmacokinetics of ...... ease, in healthy participants.
@en
Safety and pharmacokinetics of ...... ease, in healthy participants.
@nl
prefLabel
Safety and pharmacokinetics of ...... ease, in healthy participants.
@en
Safety and pharmacokinetics of ...... ease, in healthy participants.
@nl
P2093
P2860
P356
P1476
Safety and pharmacokinetics of ...... ease, in healthy participants.
@en
P2093
Andreas Schrödter
Barbara Miletzki
Gonzalo de Miquel
Josep M Jansat
Matthias Gurniak
Rosa Lamarca
P2860
P304
P356
10.1177/0091270009336353
P577
2009-07-10T00:00:00Z